English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
JSKN033
JSKN016
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
JSKN033
JSKN016
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
NEWS
Press Release
Media Report
Year:
Select
2024
2023
2022
2021
2020
2019
2018
2016
Press Release
14
March 2024
Alphamab Oncology to Present Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors at AACR 2024
Clinical data from the dose-escalation stage (phase Ia) of this study will be presented at this AACR conference
06
February 2024
The Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications
KN046 combined with nab-paclitaxel in the first-line treatment of TNBC showed encouraging PFS and OS
25
Janurary 2024
Alphamab Oncology and 3DMedicines Entered into a Licensing Agreement with Glenmark for KN035
The notable advantages of Envafolimab in terms of safety, convenience, and compliance position it as a competitive product.
09
Janurary 2024
Alphamab Oncology Announced Innovative Bispecific Antibody Coupling Drug JSKN016 Clinical Study Accepted by CDE
JSKN016 is a bispecific antibody conjugated drug (ADC) targeting HER3 and TROP2
11
December 2023
Alphmab's Novel Subcutaneous Anti-HER2 Bispecific ADC JSKN033 Approved for Clinical Studies in Australia
JSKN033 is a subcutaneous injection compound consisting of JSKN003 and envafolimab
07
December 2023
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer
KN026 in combination with docetaxel is well tolerated and has shown promising clinical benefit as 1L treatment for HER2-positive BC
04
December 2023
First Patient Dosed in Phase Ⅲ Study of JSKN003 for the Treatment of Advanced HER2-Low Breast Cancer
is a phase III clinical study in patients with unresectable locally advanced or metastatic HER2 low-expressing breast cancer
07
November 2023
KN026 was Granted Breakthrough Therapy Designation by CDE
KN026 is expected to become the first anti-HER2 treatment for second-line gastric cancer where HER2-targeted therapy has failed.
24
October 2023
Alphamab Oncology updated data from two studies of KN026 in combination with docetaxel for HER2-positive breast cancer at ESMO
the results of two studies of HER2 bispecific antibody KN026 were presented at the European Society of Medical Oncology (ESMO) Annual Meeting
24
October 2023
Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO
the results of four studies of PD-L1/CTLA-4 bispecific antibody KN046 were presented at the European Society of Medical Oncology (ESMO) Annual Meeting
1
2
3
4
PREV
1/17
NEXT